hearing loss/breast neoplasms

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 37 rezilta yo

Atypical hearing loss in women with breast cancer receiving adjuvant treatment.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

There are no reports of adjuvant treatments for early breast cancer causing hearing loss. Yet in this exploratory study 14/16 women who had received Fluorouracil, Epirubicin and Cyclophosphamide (FEC) chemotherapy regimen, 11 of whom also received endocrine treatment, had reduced hearing

Bilateral sensorineural hearing loss after adjuvant treatment with cyclophosphamide, methotrexate, Fluorouracil and alternative oral medications in a male with breast cancer.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Seventeen patients with advanced breast cancer were treated with cis-diamminedichloroplatinum (DDP) 100 mg per m2 every 21--28 days. Hydration and mannitol or furosemide diuresis was given. Responses were seen in two patients (one complete, one objective) with soft-tissue metastases. There was no

Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE The safety and efficacy of a docetaxel-cisplatin combination (DC) were evaluated in 41 patients pretreated for advanced breast cancer (ABC). METHODS The first 2 patients received 85 mg/m2 docetaxel followed, 6 hours later, by 80 mg/m2 cisplatin repeated every 3 weeks; the other 39 received

Ototoxicity after high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin followed by stem cell transplantation in patients with breast cancer.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Our purpose was to determine the risk of ototoxicity in breast cancer patients receiving a myeloablative regimen consisting of cyclophosphamide 6000 mg/m2, thiotepa 500 mg/m2 and carboplatin 800 mg/m2 (CTCb) followed by stem cell transplantation. Fourteen consecutive patients with breast cancer were

Superficial Siderosis Misdiagnosed As Parkinson's Disease in a 70-year-old Male Breast Cancer Survivor.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

A 70-year-old African American male with a history of hypertension, congestive heart failure, breast cancer status-post six rounds of doxorubicin/cyclophosphamide, and Parkinson's disease managed with carbidopa/levodopa presented to the emergency department with bilateral hearing loss and ataxia.

Hearing loss due to metastasis of gastric cancer to temporal bone: A case report.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Metastatic temporal bone tumors are rare, and tend to be asymptomatic. The clinical symptoms consist of aural discharge, bleeding, hearing loss and facial nerve paresis. The most common origin of the metastasis is breast cancer, and other sites of the primary tumor include the thyroid gland, brain,

Hearing sensitivity in women following chemotherapy treatment for breast cancer: results from a pilot study.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE Our aim was to examine in a prospective pilot study whether standard adjuvant treatments for breast cancer can adversely affect hearing. METHODS Eight pre/peri-menopausal women with breast cancer had middle ear analysis (tympanometry) and pure tone audiometry conducted prior to and 6

Phase II evaluation of gallium nitrate by continuous infusion in breast cancer.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

We evaluated the role of gallium nitrate infusion in the treatment of metastatic breast cancer. Gallium nitrate was administered at 300 mg/m2/day for 7 days every 3 weeks by continuous infusion concomitantly with oral calcium supplement of 500 mg twice daily and oral hydration. Fifteen patients with

The DFNA5 gene, responsible for hearing loss and involved in cancer, encodes a novel apoptosis-inducing protein.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

DFNA5 was first identified as a gene causing autosomal dominant hearing loss (HL). Different mutations have been found, all exerting a highly specific gain-of-function effect, in which skipping of exon 8 causes the HL. Later reports revealed the involvement of the gene in different types of cancer.

A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE A double-blind randomized Phase II chemoprevention trial of alpha-difluoromethylornithine (DFMO) was conducted in a group of women at high risk for development of breast cancer. DFMO is an irreversible inhibitor of ornithine decarboxylase, the limiting enzyme of polyamine synthesis that is

Middle ear metastasis from dormant breast cancer as the initial sign of disseminated disease 20 years after quadrantectomy.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

We describe an unusual case of breast cancer metastatic to the middle ear in a 71-year-old woman. The metastasis was the initial sign of disseminated disease 20 years after the patient had undergone a quadrantectomy for her primary disease. Computed tomography (CT) demonstrated the presence of an

Cochlear Impairment and Autoimmune Ear Disorder in a Patient with Breast Cancer.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The purpose of this study was to consider the possible role of autoimmune diseases and paraneoplastic syndrome in the genesis of tinnitus. The incidence of autoimmune inner ear disease (AIED) is rare, accounting for <1% of all cases of hearing impairment and dizziness. In presence of auditory and

Crystal structure of a dimerization domain of human Caprin-1: insights into the assembly of an evolutionarily conserved ribonucleoprotein complex consisting of Caprin-1, FMRP and G3BP1.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Caprin-1 plays roles in many important biological processes, including cellular proliferation, innate immune response, stress response and synaptic plasticity. Caprin-1 has been implicated in several human diseases, including osteosarcoma, breast cancer, viral infection, hearing loss and

[Carcinomatous meningitis].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Carcinomatous meningitis is a serious complication of advanced stage solid tumours, which may become more common with improved survival. METHODS A 53-year-old woman with a recent history of breast cancer (pT2pN2M0) had been treated by mastectomy and adjuvant chemotherapy and radiotherapy.

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye